苦参黄芪汤联合艾迪注射液治疗原发性肝癌的效果评价

doi:10.11958/20242336

天津医药 ›› 2025, Vol. 53 ›› Issue (4): 429-433.doi: 10.11958/20242336

苦参黄芪汤联合艾迪注射液治疗原发性肝癌的效果评价

于光华¹(), 宋春燕²^,^△(), 宋雪³

1 解放军第八十二集团军医院儿科（邮编071000）
2 衡水市第四人民医院中医科
3 衡水市中医医院中医内科

收稿日期:2024-12-24 修回日期:2025-02-11 出版日期:2025-04-15 发布日期:2025-04-17
通讯作者: ^△ E-mail：xzipj71@163.com
作者简介:于光华（1982），男，主治医师，主要从事中医内科方面研究。E-mail：yugh211@163.com
基金资助:
河北省中医药类科学研究课题计划项目(2024513)

Effect evaluation of Kushen Huangqi decoction combined with Aidi injection in the treatment of primary liver cancer

YU Guanghua¹(), SONG Chunyan²^,^△(), SONG Xue³

1 Department of Pediatrics, 82nd Group Military Hospital of PLA, Hengshui 071000, China
2 Department of Traditional Chinese Medicine, the Fourth People's Hospital of Hengshui
3 Department of Traditional Chinese Medicine, Hengshui Traditional Chinese Medicine Hospital

Received:2024-12-24 Revised:2025-02-11 Published:2025-04-15 Online:2025-04-17
Contact: ^△ E-mail：xzipj71@163.com

于光华, 宋春燕, 宋雪. 苦参黄芪汤联合艾迪注射液治疗原发性肝癌的效果评价[J]. 天津医药, 2025, 53(4): 429-433.

YU Guanghua, SONG Chunyan, SONG Xue. Effect evaluation of Kushen Huangqi decoction combined with Aidi injection in the treatment of primary liver cancer[J]. Tianjin Medical Journal, 2025, 53(4): 429-433.

摘要/Abstract

摘要：

目的探讨苦参黄芪汤联合艾迪注射液治疗原发性肝癌的疗效及对免疫功能和生活质量的影响。方法纳入110例原发性肝癌患者并采用随机数字表法分为联合组55例和对照组55例。对照组在常规治疗的基础上使用艾迪注射液（50 mL），联合组在对照组基础上加用苦参黄芪汤。比较2组治疗1个月后的效果以及治疗前后生活质量[Karnofsky功能状态（KPS）评分、健康状况调查简表（SF-36）]、中医症候积分、肝功能指标[总胆红素（TBIL）、天冬氨酸转氨酶（AST）、丙氨酸转氨酶（ALT）]和免疫功能指标差异。结果治疗后，2组患者的KPS评分、SF-36评分、CD4⁺、CD4⁺/CD8⁺均增加，且联合组高于对照组；2组中医症候积分、AST、TBIL、ALT和CD8⁺均降低，且联合组低于对照组（P<0.05）。结论苦参黄芪汤联合艾迪注射液治疗原发性肝癌有利于增强患者免疫功能，降低中医症候积分和肝功能损伤，提高疗效和生活质量。

关键词: 艾迪注射液, 药物疗法, 联合, 药物评价, 生活质量, 苦参黄芪汤, 原发性肝癌, 免疫功能

Abstract:

Objective To investigate the therapeutic effect of Kushen Huangqi decoction combined with Aidi injection on primary liver cancer and its impacts on immune function and quality of life. Methods A total of 110 patients with primary liver cancer were randomly divided into the combined group (n=55) and the control group (n=55). The control group was treated with Aidi injection (50 mL) on the basis of routine treatment, and the combined group was treated with Kushen Huangqi decoction on the basis of the control group. The healing effects, traditional Chinese medicine (TCM) symptom scores, quality of life[Karnofsky Performance Status (KPS) score, the MOS 36-item short-form health survey (SF-36)], liver function indicators[total bilirubin (TBIL), aspartate aminotransferase (AST), alanine aminotransferase (ALT)] and immune function indicators before and after treatment were compared between the two groups. Results After treatment, the KPS score, SF-36 score, CD4⁺ and CD4⁺/CD8⁺ were increased in the two groups, and those in the combined group were higher than the control group. The TCM symptom scores, AST, TBIL, ALT and CD8⁺ were decreased in the two groups, and those in the combined group were lower than those in the control group (P<0.05). Conclusion The combination of Kushen Huangqi decoction and Aidi injection is beneficial for enhancing immune function, reducing Chinese medicine syndrome scores and liver function damage, improving efficacy and quality of life in treating primary liver cancer.

Key words: Ai Di Zhu She Ye, drug therapy, combination, drug evaluation, quality of life, Kushen Huangqi Decoction, primary liver cancer, immune function

中图分类号:

R735.7，R286.91

图/表 6

参考文献 26

[1]	LI X, RAMADORI P, PFISTER D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer[J]. Nat Rev Cancer, 2021, 21(9):541-557. doi:10.1038/s41568-021-00383-9.
[2]	刘欣, 李丽. 原发性肝癌患者体液变化的研究[J]. 天津医药, 2021, 49(7):756-759.
	LIU X, LI L. The study on changes of body fluid in patients with primary liver cancer[J]. Tianjin Med J, 2021, 49(7):756-759. doi:10.11958/20203264.
[3]	李佳颖, 曾普华. 曾普华基于”癌毒致病”和”方证辨证”治疗肝癌临床经验[J]. 亚太传统医药, 2022, 18(5):107-110.
	LI J Y, ZENG P H. Zeng Puhua’s clinical experience in treating liver cancer based on “Cancer Toxic Disease” and “Differential and Syndrome Dialectics”[J]. Asia-Pacific Tra M, 2022, 18(5):107-110. doi:10.11954/ytctyy.202205025.
[4]	何亚莉, 杨志一, 强依凡, 等. 中药汤剂消癌化癖饮对原发性肝癌TACE术后患者血管生成因子及临床疗效的影响[J]. 中国医药导刊, 2022, 24(10):998-1003.
	HE Y L, YANG Z Y, QIANG Y F, et al. Effects of Xiaoaihuapi decoction on angiogenesis factors and clinical efficacy in patients with primary liver cancer after TACE[J]. Chinese Journal of Medicinal Guide, 2022, 24(10):998-1003. doi:10.3969/j.issn.1009-0959.2022.10.009.
[5]	中华中医药学会肝胆病分会, 李秀惠. 原发性肝癌中医诊疗指南[J]. 临床肝胆病杂志, 2024, 40(5):919-927.
	Hepatobiliary Disease Branch of the Chinese Association of Traditional Chinese Medicine,LI X H. Guideline for traditional Chinese medicine diagnosis and treatment of primary liver cancer[J]. Journal of Clinical Hepatology, 2024, 40(5):919-927. doi:10.12449/JCH240509.
[6]	YANG M, SHEN C, ZHU S J, et al. Chinese patent medicine Aidi injection for cancer care:an overview of systematic reviews and meta-analyses[J]. J Ethnopharmacol, 2022,282:114656. doi:10.1016/j.jep.2021.114656.
[7]	苏玉茜, 胡鑫, 韩涛. 基于肿瘤微环境学说探讨苦参黄芪汤对原发性肝癌患者血清生长因子及免疫功能的影响[J]. 辽宁中医杂志, 2023, 50(4):55-59.
	SU Y Q, HU X, HAN T. Effect of kushen huangqi decoction on serum growth factors and lmmune function of patients with primary liver cancer (based on tumor microenvironment theory)[J]. Liaoning Journal of Traditional Chinese Med, 2023, 50(4):55-59. doi:10.13192/j.issn.1000-1719.2023.04.016.
[8]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华肝脏病杂志, 2020, 28(2):112-128.
	Medical Administration and Medical Management Bureau, National Health Commission,PRC. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. Chinese Journal of Hepatology, 2020, 28(2):112-128. doi:10.3760/cma.j.issn.1007-3418.2020.02.004.
[9]	中国中西医结合学会活血化瘀专业委员会. 实用血瘀证诊断标准[J]. 中国中西医结合杂志, 2016, 36(10):1163.
	Professional Committee for Promoting Blood Circulation and Removing Stasis of the Chinese Society of Integrated Traditional Chinese and Western Medicine. Practical diagnostic criteria of blood stasis syndrome[J]. Chin J Integr Tradit West Med, 2016, 36(10):1163. doi:10.7661/CJIM.2016.10.1163.
[10]	EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteriain solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-227.
[11]	FRIENDLANDER A H, ETTINGER R L. Karnofsky performance status scale[J]. Spec Care Dentist, 2009, 29(4):147-148. doi:10.1111/j.1754-4505.2009.00088.x.
[12]	王坤. 健康状况调查简表(SF-36)[J]. 中华神经外科杂志, 2012, 28(6):571.
	WANG K. The MOS item short from health survey(SF-36)[J]. Chin J Neurosurg, 2012, 28(6):571.
[13]	郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002.
	ZHENG X Y. Guiding principles for clinical research of new Chinese medicine(Trial)[M]. Beijing: China Pharmaceutical Science and Technology Press, 2002.
[14]	BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi:10.3322/caac.21834.
[15]	Global Burden of Disease Cancer Collaboration,FITZMAURICE C. Global,regional,and national cancer incidence,mortality,years of life lost,years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to 2017:a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2019, 5(12):1749-1768. doi:10.1001/jamaoncol.2019.2996.
[16]	王远珍, 魏红艳, 常丽仙, 等. 原发性肝癌干预前并发肺部感染风险预测模型的建立与验证[J]. 天津医药, 2024, 52(9):940-945.
	WANG Y Z, WEI H Y, CHANG L X, et al. Establishment and validation of a risk prediction model for primary liver cancer complicated with pulmonary infection before intervention[J]. Tianjin Med J, 2024, 52(9):940-945. doi:10.11958/20240147.
[17]	姜爱萍, 濮忠建. 温阳化癥汤联合化疗治疗中晚期肝癌效果及对化疗不良反应的影响[J]. 中医药学报, 2024, 52(12):99-103.
	JIANG A P, PU Z J. Effect of wenyang huazheng decoction combined with chemotherapy in the treatment of advanced liver cancer and its impact on chemotherapy-related adverse reactions[J]. Acta Chinese Medicine and Pharmacology, 2024, 52(12):99-103. doi:10.19664/j.cnki.1002-2392.240257.
[18]	WANG J, LI G, YU L, et al. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer:a meta-analysis of 42 RCTs following the PRISMA guidelines[J]. J Ethnopharmacol, 2018, 221:137-150. doi:10.1016/j.jep.2018.04.013.
[19]	李开双, 罗茜怡, 农志欢, 等. 鸡血藤活性成分及抗肿瘤作用研究[J]. 医学信息, 2023, 36(7):176-179,188.
	LI K S, LUO Q Y, NONG Z H, et al. Research progress on active components and anti-tumor effects of suberect spatholobus stem[J]. Medical Information, 2023, 36(7):176-179,188. doi:10.3969/j.issn.1006-1959.2023.07.036.
[20]	邢明远, 黄清云, 苏乙花. 正肝化症汤联合艾迪注射液对原发性肝癌患者肝功能的影响[J]. 世界中医药, 2019, 14(11):2983-2987.
	XING M Y, HUANG Q Y, SU Y H. Effects of Zhenggan Huazheng Decoction combined with Addie Injection on liver function of patients with primary liver cancer[J]. World Chinese Medicine, 2019, 14(11):2983-2987. doi:10.3969/j.issn.1673-7202.2019.11.034.
[21]	WANG C Q, ZHENG X T, CHEN X F, et al. The optimal adjuvant strategy of aidi injection with gemcitabine and cisplatin in advanced non-small cell lung cancer:a meta-analysis of 70 randomized controlled trials[J]. Front Pharmacol, 2021,12:582447. doi:10.3389/fphar.2021.582447.
[22]	胡帅航, 王烁, 徐思雨, 等. 艾迪注射液联合FOLFOX4化疗方案治疗中晚期结直肠癌的系统评价[J]. 药物评价研究, 2022, 45(7):1387-1398.
	HU S H, WANG S, XU S Y, et al. Systematic review of Aidi Injection in combination with FOLFOX4 chemotherapy regimen for treatment of intermediate to advanced colorectal cancer[J]. Drug Evaluation Research, 2022, 45(7):1387-1398. doi:10.7501/j.issn.1674-6376.2022.07.022.
[23]	LU P, ZHANG W, CHEN L, et al. ICG fluorescence imaging technology in laparoscopic liver resection for primary liver cancer:a meta-analysis[J]. Math Biosci Eng, 2023, 20(9):15918-15941. doi:10.3934/mbe.2023709.
[24]	王浩艺, 何胜利, 殷保兵, 等. 二术解毒汤治疗中晚期脾虚湿热型原发性肝癌的疗效观察[J]. 中医药学报, 2024, 52(9):54-59.
	WANG H Y, HE S L, YING B B, et al. Efficacy of erzhu jiedu decoction on mid-to-late stage primary liver cancer with spleen-deficiency and damp-heat type[J]. Acta Chinese Medicine and Pharmacology, 2024, 52(9):54-59. doi:10.19664/j.cnki.1002-2392.240181.
[25]	燕彩霞, 王达, 魏传霞, 等. 酸味方对原发性肝癌经导管肝动脉化疗栓塞术后血清AFP、CEA、CA-125及CD4⁺/CD8⁺水平的影响[J]. 中华中医药学刊, 2024, 42(8):98-102.
	YAN C X, WANG D, WEI C X, et al. Effects of Suanwei Formula(酸味方) on Levels of AFP,CEA,CA-125 and CD4⁺/CD8⁺in serum after TACE operation for primary liver cancer[J]. Chinese Archives of Traditional Chinese Medicine, 2024, 42(8):98-102. doi:10.13193/j.issn.1673-7717.2024.08.021.
[26]	ZHOU W, DENG J, CHEN Q, et al. Expression of CD4⁺CD25⁺CD127^Low regulatory T cells and cytokines in peripheral blood of patients with primary liver carcinoma[J]. Int J Med Sci, 2020, 17(6):712-719. doi:10.7150/ijms.44088.

组别	性别（男/女）	年龄/ 岁	病程/ 年	TNM分期			Child-Pugh分级
组别	性别（男/女）	年龄/ 岁	病程/ 年	Ⅱ	Ⅲ	Ⅳ	A级	B级
对照组	45/10	54.20±5.11	1.28±0.28	12	26	17	24	31
联合组	42/13	53.84±5.20	1.25±0.24	14	23	18	26	29
χ²或t	0.495	0.369	0.629	0.366			0.147
组别		BMI/（kg/m²）	饮酒		吸烟			乙型肝炎
对照组		22.45±1.69	29（52.73）		23（41.82）			27（49.09）
联合组		22.38±1.31	27（49.09）		24（43.64）			25（45.45）
χ²或t		0.242	0.146		0.037			0.146

组别	性别（男/女）	年龄/ 岁	病程/ 年	TNM分期			Child-Pugh分级
组别	性别（男/女）	年龄/ 岁	病程/ 年	Ⅱ	Ⅲ	Ⅳ	A级	B级
对照组	45/10	54.20±5.11	1.28±0.28	12	26	17	24	31
联合组	42/13	53.84±5.20	1.25±0.24	14	23	18	26	29
χ²或t	0.495	0.369	0.629	0.366			0.147
组别		BMI/（kg/m²）	饮酒		吸烟			乙型肝炎
对照组		22.45±1.69	29（52.73）		23（41.82）			27（49.09）
联合组		22.38±1.31	27（49.09）		24（43.64）			25（45.45）
χ²或t		0.242	0.146		0.037			0.146

组别	n	完全缓解	部分缓解	稳定	恶化	总有效
对照组	55	0	18	21	16	18（32.73）
联合组	55	0	29	19	7	29（52.73）
χ²						4.495^＊

组别	n	完全缓解	部分缓解	稳定	恶化	总有效
对照组	55	0	18	21	16	18（32.73）
联合组	55	0	29	19	7	29（52.73）
χ²						4.495^＊

组别	n		KPS评分
组别	n		治疗前		治疗后		t
对照组	55		63.29±6.30		71.62±7.19		6.411^＊＊
联合组	55		63.47±6.72		78.35±7.42		11.410^＊＊
t			0.146		4.828^＊＊
组别		SF-36评分
组别		治疗前		治疗后		t
对照组		58.60±7.76		67.24±6.61		6.402^＊＊
联合组		58.24±6.62		78.33±8.20		13.593^＊＊
t		0.264		7.811^＊＊

苦参黄芪汤联合艾迪注射液治疗原发性肝癌的效果评价

Effect evaluation of Kushen Huangqi decoction combined with Aidi injection in the treatment of primary liver cancer

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 6

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周雪冰, 葛玥铭, 董洁, 张雅婷, 匡柏旭. 中耳风险指数预测小儿胆脂瘤型中耳炎行鼓室成形术短期听力恢复不佳的价值及影响因素分析[J]. 天津医药, 2025, 53(4): 374-377.
[2]	贺金华, 魏佳楠, 王丽婷. 内镜黏膜剥离术和内镜黏膜切除术对早期胃癌患者胃肠功能影响的比较[J]. 天津医药, 2025, 53(4): 407-411.
[3]	吴静静, 张福森, 陈皓, 赵亿, 刘泉, 李冬梅. 血清Syndecan-1、endocan-1联合qSOFA评分在脓毒症诊断及预后评估中的应用价值[J]. 天津医药, 2025, 53(2): 185-188.
[4]	王若宇, 张宇, 王佳慧, 张占霞. 复方苦参注射液减轻肝癌大鼠5-氟尿嘧啶化疗不良反应的机制研究[J]. 天津医药, 2025, 53(1): 24-28.
[5]	秦汉林, 胡长路, 赵亚梅, 牛维纳. 四联方案预防含顺铂方案多日化疗致恶心呕吐的效果和安全性研究[J]. 天津医药, 2024, 52(8): 835-839.
[6]	吴倩, 王意, 陈念, 周凯, 田昕, 徐晖, 苟小霞. 诱导化疗对鼻咽癌患者免疫功能及炎症指标的影响[J]. 天津医药, 2024, 52(4): 397-402.
[7]	张晓旭, 杨文奇. 沙库巴曲缬沙坦治疗AMI后射血分数中间值心力衰竭的疗效研究[J]. 天津医药, 2024, 52(2): 177-181.
[8]	杨文珊, 盛玉, 陈秀利, 陈吉. 小儿急性胰腺炎序贯化营养支持与肠外营养支持的疗效比较[J]. 天津医药, 2024, 52(10): 1061-1064.
[9]	雷敏, 蔡春泉. 类器官在儿童遗传性疾病中的应用研究进展[J]. 天津医药, 2024, 52(1): 33-37.
[10]	张晓宇, 任悦, 刘伟, 苗彦玲, 张辉, 靳丽君, 张恒乐, 康晓宁, 白杰, 王遵义. 新辅助化疗联合PD-1抑制剂治疗三阴性乳腺癌的临床疗效[J]. 天津医药, 2023, 51(8): 847-850.
[11]	聂亚蒙, 张小强, 冯鹏展, 丁雅倩. 依达拉奉右莰醇联合rt-PA静脉溶栓治疗超早期急性脑梗死的疗效及对预后的影响[J]. 天津医药, 2023, 51(7): 766-770.
[12]	杨超, 张志永. 2型糖尿病患者结直肠腺瘤发病的多因素风险预测模型构建[J]. 天津医药, 2023, 51(1): 95-99.
[13]	胡加海, 薛松, 陈荃. 卡瑞利珠单抗联合化疗方案对中晚期食管癌患者血清miR-21、可溶性E-钙黏蛋白表达的影响[J]. 天津医药, 2022, 50(8): 873-877.
[14]	陈健, 杨莉, 金杰, 王磊, 董敏, 柴国祥. 胸腔引流微管与胸腔镜治疗肺气肿合并巨大肺大疱的临床疗效比较[J]. 天津医药, 2022, 50(7): 761-765.
[15]	王静, 辛绍斌, 孙强, 马旺, 齐勇, 王永明, 申翔. 以多黏菌素B为基础联合治疗耐碳青霉烯革兰阴性菌脓毒症的临床疗效分析[J]. 天津医药, 2022, 50(1): 88-93.

组别	纳呆			胁痛
组别	治疗前	治疗后	t	治疗前	治疗后	t
对照组	1.56±0.21	1.18±0.14	12.307^＊＊	1.80±0.21	1.45±0.17	9.815^＊＊
联合组	1.53±0.18	0.85±0.12	21.021^＊＊	1.78±0.23	1.21±0.14	17.522^＊＊
t	0.765	13.088^＊＊		0.429	7.895^＊＊
组别	舌紫黯			痞块
组别	治疗前	治疗后	t	治疗前	治疗后	t
对照组	2.31±0.27	1.58±0.18	17.369^＊＊	1.65±0.19	1.44±0.16	6.069^＊＊
联合组	2.35±0.26	1.02±0.11	33.893^＊＊	1.62±0.18	0.93±0.11	24.078^＊＊
t	0.958	19.640^＊＊		1.107	19.989^＊＊

组别	纳呆			胁痛
组别	治疗前	治疗后	t	治疗前	治疗后	t
对照组	1.56±0.21	1.18±0.14	12.307^＊＊	1.80±0.21	1.45±0.17	9.815^＊＊
联合组	1.53±0.18	0.85±0.12	21.021^＊＊	1.78±0.23	1.21±0.14	17.522^＊＊
t	0.765	13.088^＊＊		0.429	7.895^＊＊
组别	舌紫黯			痞块
组别	治疗前	治疗后	t	治疗前	治疗后	t
对照组	2.31±0.27	1.58±0.18	17.369^＊＊	1.65±0.19	1.44±0.16	6.069^＊＊
联合组	2.35±0.26	1.02±0.11	33.893^＊＊	1.62±0.18	0.93±0.11	24.078^＊＊
t	0.958	19.640^＊＊		1.107	19.989^＊＊

组别	n	AST/（U/L）			TBIL/（μmol/L）			ALT/（U/L）
组别	n	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	55	85.43±10.38	48.66±5.44	23.238^＊＊	34.56±4.53	18.74±2.31	21.207^＊＊	105.12±11.59	63.15±7.45	20.368^＊＊
联合组	55	85.71±9.53	35.09±3.87	35.012^＊＊	34.28±3.89	12.95±1.71	39.137^＊＊	104.33±12.32	41.70±4.83	34.733^＊＊
t		0.147	15.083^＊＊		0.335	14.961^＊＊		0.346	17.912^＊＊

组别	n	AST/（U/L）			TBIL/（μmol/L）			ALT/（U/L）
组别	n	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	55	85.43±10.38	48.66±5.44	23.238^＊＊	34.56±4.53	18.74±2.31	21.207^＊＊	105.12±11.59	63.15±7.45	20.368^＊＊
联合组	55	85.71±9.53	35.09±3.87	35.012^＊＊	34.28±3.89	12.95±1.71	39.137^＊＊	104.33±12.32	41.70±4.83	34.733^＊＊
t		0.147	15.083^＊＊		0.335	14.961^＊＊		0.346	17.912^＊＊